Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Hypoxia-induced adenosine creates an immunosuppressive tumor microenvironment (TME) and dampens the efficacy of immune checkpoint inhibitors (ICIs). We found that hypoxia-inducible factor 1 (HIF-1) orchestrates adenosine efflux through two steps in hepatocellular carcinoma (HCC). First, HIF-1 activates transcriptional repressor MXI1, which inhibits adenosine kinase (ADK), resulting in the failure of adenosine phosphorylation to adenosine monophosphate. This leads to adenosine accumulation in hypoxic cancer cells. Second, HIF-1 transcriptionally activates equilibrative nucleoside transporter 4, pumping adenosine into the interstitial space of HCC, elevating extracellular adenosine levels. Multiple in vitro assays demonstrated the immunosuppressive role of adenosine on T cells and myeloid cells. Knockout of ADK in vivo skewed intratumoral immune cells to protumorigenic and promoted tumor progression. Therapeutically, combination treatment of adenosine receptor antagonists and anti–PD-1 prolonged survival of HCC-bearing mice. We illustrated the dual role of hypoxia in establishing an adenosine-mediated immunosuppressive TME and offered a potential therapeutic approach that synergizes with ICIs in HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3. Adenosine promotes Treg differentiation and cell death while suppressing T cell proliferation and functions. (A) CellTrace Violet (CTV) T cell proliferation assay on (left) CD8+ and (right) CD4+ T cells treated with indicated doses of NECA (adenosine stable analog) for 3 days with IL-2. (B) Percentages of (left) IFN-γ+ and (right) granzyme B+ CD8+ T cells treated with indicated doses of NECA for 3 days with IL-2. (C) Percentage of cell death of (left) CD8+ and (right) CD4+ T cells treated with indicated doses of NECA for 3 days with IL-2. (D) Splenic T cells were cultured with 100 μM NECA in the presence of vehicle [dimethyl sulfoxide (DMSO)], 100 nM A2AR antagonist (ZM241385), or 100 nM A2BR antagonist (CVT6883) for 3 days with IL-2. The percentage of Tregs (CD4+ CD25+FOXP3+) was determined by flow cytometry. (E to H) Bulk RNA sequencing was performed on NECA-treated T cells compared to vehicle (DMSO). (E) to (G) GSEA showed the enrichment of selected gene sets in NECA-treated T cells. (H) Fold change of selected genes as compared to vehicle. Error bars indicate means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 versus 0 μM or DMSO as indicated. Student’s t test. ns, not significant.](https://figures.cochat.ai/paper-figures/0d68e93bfa9e4ed29df3e2a43cc9adad/hypoxia-inducible-factor-orchestrates-adenosine-metabolism-to-promote-liver-figure-3.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Inhibition of either ENTPD2 or ADK enhanced the activity of immune checkpoint inhibitors, which highlights their significance in driving immunosuppression and their potential utility as therapeutic targets to enhance the efficacy of immune checkpoint inhibitors [90, 93].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [93]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, HIF activates transcriptional repressor MXI1, which inhibits ADK, resulting in adenosine accumulation in hypoxic cancer cells [93].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [93]
The cited source says what the claim attributes to it.
In the citing paper
“The HIFs also transcriptionally activate ENT4, which pumps adenosine into the interstitial space, elevating extracellular adenosine levels, which is associated with immunosuppressive effects [93].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“Hypoxia induces transcriptional activation of multiple genes involved in tumor development including cancer cell proliferation, angiogenesis, and migration ( 46 ).”
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Cited by
Metabolic reprogramming in the tumor microenvironment of liver cancer
Lin, J., Rao, D., Zhang, M., & Gao, Q. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01527-8 · Cited by 251
“This results in adenosine-mediated immunosuppressive roles on T cells and myeloid cells [149, 150].”
BackgroundSelf-citationYin, Y., Feng, W., Chen, J., Chen, X., Wang, G., Wang, S., Xu, X., Nie, Y., Fan, D., Wu, K., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00539-x · Cited by 137
Nanocatalysts for modulating antitumor immunity: fabrication, mechanisms and applications
Wu, X., Li, Y., Wen, M., Xie, Y., Zeng, K., Liu, Y., Chen, W., & Zhao, Y. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00673e · Cited by 99
Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy
Zhang, H., Fan, J., Kong, D., Sun, Y., Zhang, Q., Xiang, R., Lu, S., Yang, W., Feng, L., & Zhang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02460-1 · Cited by 58
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
The role of metabolic reprogramming in liver cancer and its clinical perspectives
Lu, M., Wu, Y., Xia, M., & Zhang, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1454161 · Cited by 46
Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies
Wang, X., He, J. N., Ding, G., Tang, Y., & Wang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688699 · Cited by 66
“High intratumoral adenosine levels are associated with resistance to ICIs, and drugs targeting the adenosine pathway (CD73 inhibitors or A2A receptor antagonists) are being tested in combination with ICIs (83).”
Hypoxia-Induced Signaling in Gut and Liver Pathobiology
Solanki, S. A., & Shah, Y. M. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051122-094743 · Cited by 38
CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1α
Fu, X., Zhang, Q., Wang, Z., Xu, Y., & Dong, Q. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06398-4 · Cited by 28
Benzothiazole derivatives in the design of antitumor agents
Paoletti, N., & Supuran, C. T. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400259 · Cited by 33
Metabolic immunoengineering approaches to enhance CD8+ T cell-based cancer immunotherapy
Feng, B., Li, R., Li, W., & Tang, L. (2024) · Cell Systems · doi:10.1016/j.cels.2024.11.010 · Cited by 29
Sun, K., Wei, X., Han, S., Sun, Y., Xiao, H., & Wei, D. (2025) · ACS Nano · doi:10.1021/acsnano.5c00691 · Cited by 25
Overview of the role of purinergic signaling and insights into its role in cancer therapy
Virgilio, F. D., Vultaggio-Poma, V., Tarantini, M., & Giuliani, A. L. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108700 · Cited by 27
Huang, T., Ren, X., Tang, X., Wang, Y., Ji, R., Guo, Q., Ma, Q., Zheng, Y., Hu, Z., & Zhou, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1427380 · Cited by 31
“The novel A2aR antagonist DZD2269 could reverse the immunosuppression induced by high concentration eAdo and play a more signi fi cant anti-tumor effect when combined with ICIs, radiotherapy, or chemotherapy (23).”
BackgroundInfluentialWang, P., Zhang, X., Liu, F., & Wang, W. (2025) · Research · doi:10.34133/research.0651 · Cited by 30
Fan, M., Yang, P., Huo, L., Bao, J., Tan, M., Zeng, J., Zhu, S., Liu, M., Zhao, J., Miao, W., et al. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.01.044 · Cited by 17
Path to bacteriotherapy: From bacterial engineering to therapeutic perspectives
Liu, J., He, C., Tan, W., & Zheng, J. H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122897 · Cited by 15
The Role of Macrophages in Hepatocellular Carcinoma and Their Therapeutic Potential
Bannister, M. E., Chatterjee, D. A., Shetty, S., & Patten, D. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313167 · Cited by 17
Hypoxia-adenosine axis as therapeutic targets for acute respiratory distress syndrome
Figarella, K., Kim, J., Ruan, W., Mills, T., Eltzschig, H. K., & Yuan, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328565 · Cited by 16
Intercellular crosstalk shapes purinergic metabolism and signaling in cancer cells
Hesse, J., Steckel, B., Dieterich, P., Aydin, S., Deußen, A., & Schrader, J. (2024) · Cell Reports · doi:10.1016/j.celrep.2023.113643 · Cited by 12
Adenosine Kinase: An Epigenetic Modulator and Drug Target
Peter-Okaka, U. I., & Boison, D. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70033 · Cited by 14
“Consequently, in HCC, it has been reported that mice treated with adenosine receptor antagonists and anti- PD-1 (programmed cell death protein 1) monoclonal antibodies experienced prolonged survival [122].”
Chen, Y., Li, X., Wang, Z., Yuan, S., Shen, X., Xie, X., Xing, K., & Zhu, Q. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00859-y · Cited by 13
Shan, L., Gong, M., Zhai, D., Meng, X., Liu, J., & Lv, X. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03416-5 · Cited by 13
“HCC cells generate immunosuppressive signals mainly by increasing adenosine levels in the microenvironment [98].”
Development of small molecule inhibitors of hypoxia-inducible factors for cancer therapy
Semenza, G. L. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100075 · Cited by 12
Akabane, M., Imaoka, Y., Lee, G. R., & Pawlik, T. M. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2568904 · Cited by 10
“Furthermore, HIF-1α can modulate the adenosine metabolic pathway within tumor cells, leading to the accumulation of extracellular adenosine [74].”
“Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach“
Li, X., & Song, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1646292 · Cited by 13
Regulatory T Cell Metabolism in Cancer
Mortezaee, K. (2025) · Immunology · doi:10.1111/imm.70096 · Cited by 192
“Tregs express CD39, and cancer cells express CD73 [46].”
InfluentialChen, Y., Zhou, G., Li, Y., Liu, S., Xu, Q., & Liu, X. (2025) · Talanta · doi:10.1016/j.talanta.2025.127750 · Cited by 8
Pallio, G., & Mannino, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157241 · Cited by 9
Adenosine metabolic clearance maintains liver homeostasis by licensing arginine methylation of RIPK1
Liu, R., Wang, G., Jiang, Z., Zou, T., Wang, C., Wang, W., Cai, M., Zhang, S., Wang, G., Cao, H., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20250603 · Cited by 8
Zhang, H., Han, B., Tian, S., Gong, Y., & Liu, L. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5693 · Cited by 9
“…it has been discovered that HIF‑1 may be linked to hypoxia‑induced micropino‑ cytosis in HCC, resulting in the absorption of extracellular fluids and promoting cell proliferation, whereas specific knockdown of HIF‑1 was shown to significantly inhibit HCC progression and proliferation (51,52).”
BackgroundYang, H., Lei, M. M. L., Xie, L., Shou, Y., & Lee, T. K. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1068 · Cited by 12
Zhang, X., Sun, J., Guo, J., Hu, X., Zhou, J., Xie, X., Chen, X., Luo, H., Liu, H., & Tian, Y. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02210-2 · Cited by 9
“A plausible explanation is that the reduced blood flow and vascular dysfunction commonly seen in SSc lead to tissue hypoxia, a strong inducer of adenosine production [24, 25].”
Wang, Y., Zhang, Z., Cao, L., Huang, S., Huang, X., Zhang, Z., Zhang, Y., & Li, X. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120492 · Cited by 7
Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation
Majumder, B., & Datta, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1676702 · Cited by 9
Chen, D., Wu, R., Liu, Z., Wei, Y., & Kuang, D. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004035 · Cited by 6
“P D - 1 b l o c k a d e [ 206 ] A d e no s i n e r ece p t o r b l o c k a d e M ou s e L i v e r c a n ce r P r ec li n i c a l C o m b i n a t i on t r e a t m e n t o f a d e no s i n e r ece p t o r a n t ag on i s t s a nd a n t i -”
Hypoxia-adenosinergic regulation of B cell responses
Pruitt, L., & Abbott, R. K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1478506 · Cited by 4
Chen, Y., Wang, K., Zhang, X., Tao, D., Shang, Y., Wang, P., Li, Q., & Liu, Y. (2024) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-024-01061-8 · Cited by 4
Self-citationHe, Z., Peng, X., Li, J., Zhu, Y., Zhang, X., Duan, J., Ni, J., Ma, M., Wang, J., Liu, Z., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.161177 · Cited by 4
Self-citationGuo, G., Zhong, W., Zhao, H., An, Y., Dong, X., Li, Z., Qin, S., Xu, G., Yue, X., Wang, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202517480 · Cited by 4
Jiang, H., Wang, X., Cai, X., Zhang, J., Kong, F., Fan, Q., & Dong, Z. (2026) · Nano Today · doi:10.1016/j.nantod.2026.102997 · Cited by 3
Unraveling the tapestry: Lessons from multi-omics and spatial biology in hepatocellular cancer
Massoudi, D., Srivastava, A., & Dhanasekaran, R. (2026) · Hepatology · doi:10.1097/hep.0000000000001716 · Cited by 6
Cellular mechanometabolism: stimuli and implications
Ortiz, I., Lopez, S., Kondapaneni, R. V., Hernández, J. A., Boone, K., & Reinhart‐King, C. A. (2026) · EMBO Reports · doi:10.1038/s44319-026-00795-4 · Cited by 4
“Hypoxic conditions driven by increased stiffness lead to HIF-1 stabilization (Cheu et al, 2023), which promotes metabolic rewiring and ECM remodeling by upregulating lysyl oxidase (LOX), a cross-linking enzyme that further stiffens the matrix (Schietke et al, 2010).”
Pan, T., Shi, X., Bao, Y., Wang, S., Li, T., Diao, Y.-P., & Meng, X. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116320 · Cited by 3
Nutritional modulation of metabolic signaling within the tumor microenvironment for cancer therapy
Aghdam, M. M., Rezagholizadeh, L., Fazaeli, A., Moradi, A., & Ojarudi, M. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05462-1 · Cited by 4
Jiaoting, E., Zhao, Y., Zhang, X., Zhang, Q. J., Xu, Y., Liu, S., Ding, H., Zhu, J., Yang, P., & Xie, R. (2026) · Science Advances · doi:10.1126/sciadv.aea6844 · Cited by 2
“Restraining the hypoxia/HIF axis offers a potential therapeutic approach that might synergize with immunotherapy in HCC ( 48 ).”
Yang, D., Zhao, F., Zhou, Y., Zhang, Y., Shen, J., Yu, B., Zhao, K., & Ding, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112076 · Cited by 3
Zhao, P., & Xu, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-03152-4 · Cited by 2
“In HCC, hypoxia fosters the activation of pathways that enhance cancer cell proliferation, migration, and invasion, while also contributing to immune evasion [21, 22].”
Fueling the fatal voyage: How metabolic plasticity empowers every step of cancer metastasis
Liao, J., & Ji, Q. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218444 · Cited by 2
Hypoxia-driven tumor immune escape: mechanisms and therapeutic opportunities
Qin, H., 杨书强, He, J., Zhao, M., Zhao, L., Wang, J., Jiang, X., Chen, X., & Xu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1893099 · Cited by 1
“In hepatocellular carcinoma models, 32-134D combined with anti-PD-1 therapy increases tumor clearance rates compared with single treatment (75).”
Wei, G., Zhu, X., Chen, X. S., Lv, J., Xiang, F., Zhang, M., Tao, K. X., Wen, W., He, D., Wu, X., et al. (2026) · Autophagy · doi:10.1080/15548627.2026.2700024 · Cited by 1
Self-citationReceptor agonist/antagonist-incorporated anticancer nanodrugs: Design, materials, and strategies
Hao, S.-J., Wu, S., Chang, Y.-K., & Wu, F. (2024) · Materials Today · doi:10.1016/j.mattod.2024.11.006 · Cited by 2
Effect and mechanism of PYCR1 on biological function of hepatocellular carcinoma cells under hypoxia
Guo, J., Jin, X., Zhang, J., Zhang, Y., & Wu, W. (2025) · Discover Oncology · doi:10.1007/s12672-025-03028-7 · Cited by 3
Chen, Q., Zeng, J., Tang, H., Sun, Y., Wu, H., Huang, X., Man, Y.-N., Li, B., & He, M. (2025) · Medicine · doi:10.1097/md.0000000000044350
“As an important transcription factor, MXI1 regulates gene expression through a competitive binding mechanism and plays a key role [31] in the cellular response to hypoxia.”
Zhu, Y., Liu, J., Zeng, J., Liu, Z., Yan, Z., Zhang, S., Luo, H., Wu, Z., Lu, J., Qiu, F., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04257-z
“MXI1 interacted with Sin3A/HDAC co-repressor complex to govern gene suppression under hypoxia [5].”
Guo, J., Huang, J., Wang, Y., Sun, J., Liu, S., Deng, C., LÜ, J., & Zhong, Z. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.03.005 · Cited by 1
Illuminating the path to oncolysis: rise of microbial phototherapy
Wu, B., Lv, X., Kang, S., Sun, J., Yao, S., Liu, M., Zhang, R., & Zhang, H. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04385-3
“Their primary antitumor mechanism entails reversing hypoxia through photosynthetic oxygenation and downregulating critical survival factors such as HIF-1α, which is pivotal in tumor drug resistance [67–69 ,”
Qiao, C., Lei, Q., Lu, L., Ding, Y., Xu, Y., Zhang, H., Song, J. H., Qiao, H., Cheng, T., & 李俊生 (2026) · Biomedical Materials · doi:10.1088/1748-605x/ae70e2
“Current therapeutic options for HCC comprise local interventions such as surgical resection, intra-arterial embolization, ablation, and radiotherapy (RT), as well as systemic treatments represented by tyrosine kinase inhibitors (TKIs) [5–7].”
Yi, X., Yang, H., Huang, J. F., Wu, P., Zhou, S., Liao, Z., Han, M., Chen, Z., Huang, X., Ma, N., et al. (2026) · Advanced Science · doi:10.1002/advs.76303
“…from (PBS + Laser)- treated cells combined with LPS and NECA (adenosine analog and a potent and non-selective adenosine receptor agonist [ 57, 58 ]) (PBS + LPS + NECA), supernatants from (SCH + Laser)- treated cells combined with LPS and NECA (SCH + LPS + NECA), supernatants from (BSC +…”
Xu, L., Wu, J., Li, C., Ke, S., Du, W., Wang, F., Gong, X., Qiao, W., Zhang, H., & Lin, J. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.119298
O 2 -sensing and HIF regulation: from oxygen homeostasis to tumor-associated immune responses
Schneider, V., Fandrey, J., & Winning, S. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00185.2026
Li, X., Yang, K., Liang, X., Qi, F., & Lv, Y. (2026) · Precision medicine and engineering. · doi:10.1016/j.preme.2026.100085
Ding, T., Xiong, T., Xu, X., Sun, Q., Liu, M., Fang, Z., Li, Y., Wu, Z., Zhang, W., Zhou, P., et al. (2026) · Biomaterials Research · doi:10.34133/bmr.0392
“This failure stems from the immunosuppressive tumor microenvironment (TME) characterized by hypoxia [ 7 , 8 ], poor immunogenic cell death (ICD), and deficient dendritic cell (DC) activation [ 9 , 10 ].”
Lotfi, E., & Golab, F. (2026) · Cancer Investigation · doi:10.1080/07357907.2026.2725033 · Cited by 2
Pan, J., Li, B., Lau, L. Y., Hong, Z., & Chen, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189702
Metadata
- Authors
- Cheu, J. W.-S., Chiu, D. K.-C., Kwan, K. K.-L., Yang, C., Yuen, V. W.-H., Goh, C. C., Chui, N. N.-Q., Shen, W., Law, C.-T., Li, Q., Zhang, M. S., Bao, M. H.-R., Wong, B. P.-Y., Chan, C. Y.-K., Liu, C. X., Sit, G. F.-W., Ooi, Z. Y., Deng, H., Tse, A. P.-W., Ng, I. O.-L., & Wong, C. C.-L.
- Affiliations
- University of Hong Kong (HK)
- Sun Yat-sen University (CN)
- Corresponding author
- Wong, Carmen Chak-Lui
- ORCID
- Venue
- Science Advances
- Published
- 2023-05-05
- Volume
- 9
- Issue
- 18
- Pages
- eade5111-eade5111
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC10162666
- OpenAlex
- W4372332351
- Cited by
- 65
- References
- 61
- Citations by year
- 2026: 20 · 2025: 24 · 2024: 20 · 2023: 1
- FWCI
- 12.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (82022077)
- University of Hong Kong
- Directorate for Biological Sciences
- Cornell Center for Materials Research
- Young Scientists Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- HIF-1, hepatocellular carcinoma, adenosine metabolism, adenosine kinase, MXI1, immunosuppressive tumor microenvironment, adenosine receptor antagonists, anti-PD-1 combination therapy, immune checkpoint inhibitors, tumor hypoxia
- MeSH terms
- Adenosine, Animals, Hypoxia, Carcinoma, Hepatocellular, Liver Neoplasms, Mice, Knockout, Cell Line, Tumor, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.